Reported studies focused on ASCT in PCNSL
| Ref . | N* . | Median age (range), y . | Therapy line . | Therapy (induction→intensification) . | CRR to induction,† % . | Transplanted patients,† % . | Conditioning regimen . | WBRT . | Median follow-up, mo . | OS, y (%) . | Neuro toxicity,† % . | TRM,† % . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | 22 | 53 (27–64) | Salvage | ARAC+VP16 | 36 | 91 | Bu/TT/Cy | No | 41 | 3 (64) | 32 | 4 |
| 61 | 43 | 52 (23–65) | Salvage | ARAC+VP16 | 35 | 63 | Bu/TT/Cy | No | 36 | 2 (45) | 5 | 12 |
| 62 | 45 | 57 (19–72) | Salvage | ICE‡ | 51 | 40 | Bu/TT | No | 53 | 5 (40) | NR | 5 |
| 63 | 28 | 53 (25–71) | First | HDMTX→ARAC | 29 | 50 | BEAM | No | 28 | 2 (55) | 0 | 4 |
| 64 | 25 | 52 (21–60) | First | MBVP→IFO+ARAC | 44 | 68 | BEAM | Yes | 34 | 4 (64) | 8 | 4 |
| 65 | 6 | 53 (30–66) | First | MBVP→IFO+ARAC | 2 of 6 patients | 6 of 6 patients§ | BEAM | Yes | 41 | 2 (40) | 2 of 6 patients | 0 of 6 patients |
| 66 | 11 | 52 (33–65) | First | HDMTX→ARAC | 8 of 11 patients | 11 of 11 patients§ | BUCYE | Yesll | 25 | 2 (89) | 3 of 11 patients | 0 of 11 patients |
| 67 | 13 | 56 (35–65) | First | MPV→ARAC | 31 | 46 | LEED | Yesll | 44 | 3 (76) | 0 | 0 |
| 68 | 23 | 55 (18–69) | First | HDMTX→ —# | 13 | 69 | Bu/TT | Yesll | 15 | 2 (48) | 39 | 13 |
| 19 | 33 | 57 (23–67) | First | R-MPV→ —# | 66 | 81 | Bu/TT/Cy | No | 45 | 3 (81) | 0 | 12 |
| 69,70 | 21 | 56 (34–69) | First | MPV→ARAC | 24 | 100§ | Bu/TT/Cy | No | 60 | 5 (44) | 0 | 24 |
| 71 | 30 | 54 (27–64) | First | HDMTX→ARAC+TT | 33 | 77 | BCNU/TT | Yes | 63 | 5 (69) | 17 | 3 |
| 72,73 | 13 | 54 (38–67) | First | HDMTX→ARAC+TT | 31 | 85 | BCNU/TT | Yesll | 72 | 5 (77) | 0 | 0 |
| 16 | 38¶ | 55 (25–60) | First | R-MBVP→R-ARAC | 38 | 62 | Bu/TT/Cy | No | 33 | 4 (65) | NR | 5 |
| 37 | 59¶ | 58 (26–70) | First | HDMTX+ARAC±R±TT | 54 | NR | BCNU/TT | No | 40 | 2 (71) | 0 | 3 |
| Ref . | N* . | Median age (range), y . | Therapy line . | Therapy (induction→intensification) . | CRR to induction,† % . | Transplanted patients,† % . | Conditioning regimen . | WBRT . | Median follow-up, mo . | OS, y (%) . | Neuro toxicity,† % . | TRM,† % . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60 | 22 | 53 (27–64) | Salvage | ARAC+VP16 | 36 | 91 | Bu/TT/Cy | No | 41 | 3 (64) | 32 | 4 |
| 61 | 43 | 52 (23–65) | Salvage | ARAC+VP16 | 35 | 63 | Bu/TT/Cy | No | 36 | 2 (45) | 5 | 12 |
| 62 | 45 | 57 (19–72) | Salvage | ICE‡ | 51 | 40 | Bu/TT | No | 53 | 5 (40) | NR | 5 |
| 63 | 28 | 53 (25–71) | First | HDMTX→ARAC | 29 | 50 | BEAM | No | 28 | 2 (55) | 0 | 4 |
| 64 | 25 | 52 (21–60) | First | MBVP→IFO+ARAC | 44 | 68 | BEAM | Yes | 34 | 4 (64) | 8 | 4 |
| 65 | 6 | 53 (30–66) | First | MBVP→IFO+ARAC | 2 of 6 patients | 6 of 6 patients§ | BEAM | Yes | 41 | 2 (40) | 2 of 6 patients | 0 of 6 patients |
| 66 | 11 | 52 (33–65) | First | HDMTX→ARAC | 8 of 11 patients | 11 of 11 patients§ | BUCYE | Yesll | 25 | 2 (89) | 3 of 11 patients | 0 of 11 patients |
| 67 | 13 | 56 (35–65) | First | MPV→ARAC | 31 | 46 | LEED | Yesll | 44 | 3 (76) | 0 | 0 |
| 68 | 23 | 55 (18–69) | First | HDMTX→ —# | 13 | 69 | Bu/TT | Yesll | 15 | 2 (48) | 39 | 13 |
| 19 | 33 | 57 (23–67) | First | R-MPV→ —# | 66 | 81 | Bu/TT/Cy | No | 45 | 3 (81) | 0 | 12 |
| 69,70 | 21 | 56 (34–69) | First | MPV→ARAC | 24 | 100§ | Bu/TT/Cy | No | 60 | 5 (44) | 0 | 24 |
| 71 | 30 | 54 (27–64) | First | HDMTX→ARAC+TT | 33 | 77 | BCNU/TT | Yes | 63 | 5 (69) | 17 | 3 |
| 72,73 | 13 | 54 (38–67) | First | HDMTX→ARAC+TT | 31 | 85 | BCNU/TT | Yesll | 72 | 5 (77) | 0 | 0 |
| 16 | 38¶ | 55 (25–60) | First | R-MBVP→R-ARAC | 38 | 62 | Bu/TT/Cy | No | 33 | 4 (65) | NR | 5 |
| 37 | 59¶ | 58 (26–70) | First | HDMTX+ARAC±R±TT | 54 | NR | BCNU/TT | No | 40 | 2 (71) | 0 | 3 |
Data were updated from reference 41. ARAC, cytarabine; BCNU, carmustine; BEAM, carmustine, etoposide, cytarabine, and melphalan; Bu, busulfan; BUCYE, busulfan, cyclophosphamide and etoposide; Cy, cyclophosphamide; HDMTX, high-dose methotrexate; ICE (regimen), ifosfamide, carboplatin, etoposide; IFO, ifosfamide; LEED, cyclophosphamide, etoposide and melphalan; MBVP (regimen), methotrexate, carmustine, etoposide, and methylprednisolone; MPV (regimen), methotrexate, vincristine, and procarbazine; NR, not reported; R-ARAC, rituximab/cytarabine; Ref, reference; R-MPV (regimen), MPV plus rituximab; TRM, treatment-related mortality; TT, thiotepa; VP16, etoposide.
*Number of assessable patients.
†Values are percentages unless otherwise indicated.
Some patients with relapsed disease were retreated with HD-MTX.
Performed ASCT was a selection criterion.
llOnly for patients not achieving a complete remission.
Randomized trials: data regard patients allocated to the ASCT arm.
These patients did not receive intensification.